Dergiler / Medicine Science / 2016 / Cilt: 5 - Sayı: 4

Combined percutaneous ethanol injection and mitoxantrone versus radiofrequency ablation in the treatment of hepatocellular carcinoma

Sayfa
948–956
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Combination of percutaneous local injection of ethanol and mitoxantrone is comparable to radiofrequency ablation with less frequent complications in the treatment of Hepatocellular Carcinoma when surgical resection or liver transplantation is not amenable or available

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:New therapeutic choices have been developed for hepatocellular carcinoma, including percutaneous ablation therapy, transarterial chemoembolization, radiation therapy and molecular target therapy.
📊
Temel Bulgular & Veri:This study included 124 patients with hepatocellular carcinoma, they were randomly divided into two groups; group I (64 patients) treated with local injection of ethanol plus mitoxantrone.
💡
Sonuç & Katkı:Combination of percutaneous local injection of ethanol and mitoxantrone is comparable to radiofrequency ablation with less frequent complications in the treatment of Hepatocellular Carcinoma when surgical resection or liver transplantation is not amenable or available
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

New therapeutic choices have been developed for hepatocellular carcinoma, including percutaneous ablation therapy, transarterial chemoembolization, radiation therapy and molecular target therapy. Ablation of liver tumors is currently the main alternative to liver resection. This work aimed at comparing percutaneous combined local injection of ethanol and mitoxantrone versus percutaneous radiofrequency ablation in the treatment of Hepatocellular Carcinoma. This study included 124 patients with hepatocellular carcinoma, they were randomly divided into two groups; group I (64 patients) treated with local injection of ethanol plus mitoxantrone. Group II (60 patients) treated with radiofrequency ablation. Clinical assessment, laboratory evaluation and CT studies were performed to all patients prior to treatment and at 1, 3, 6, and 12 months' post treatment. The percentage of ablation in both groups at 1, 3, 6 and 12 months were 81.3%, 81.3%,76.6 and 71.9% in group I respectively versus 88.3%, 88.3, 85%% and 81.7% in group II respectively with no statistical significant difference between the two groups. Percentage of ablation in small tumors is higher than large tumors in both groups. Side effects and complications are statistically higher in group II than group I. Combination of percutaneous local injection of ethanol and mitoxantrone is comparable to radiofrequency ablation with less frequent complications in the treatment of Hepatocellular Carcinoma when surgical resection or liver transplantation is not amenable or available

🔖

Bu Makaleye Atıf Yap

HELMY, B., ABDEL-WAHAB, S., EL-SHAMY, M., MONEM, S. M. A., DAWOD, H. M. (2016). Combined percutaneous ethanol injection and mitoxantrone versus radiofrequency ablation in the treatment of hepatocellular carcinoma. Medicine Science, Cilt: 5 - Sayı: 4, 948–956. https://ajindex.com/articles/277544

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. Cancer J Clin. 2005;55(2):74-108.
  2. Franca AV, Elias Junior J, Lima BL, Martinelli AL, Carrilho FG. Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res. 2004;37(11):1689-705.
  3. Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J. Gastroenterol. 2003;9(9):1885- 91. Kim JK, Han KH, Lee JT, Paik YH, Ahn SH, Lee JD,Lee KS, Chon CY, Moon YM. Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with Holmium-166-Chitosan complex (Milican®) for the treatment of small hepatocellular carcinoma. Clin Cancer Res. 2006;12(2):543-8.
  4. Wright AS, Mahvi, DM, Haemmerich DG, Lee FT. Minimally invasive approaches in management of hepatic tumors. Surg. Technol. Int. 2003;11:144-53.
  5. Zamboglou N, Wurm R, Pape H. Simultaneous radiotherapy and intratumoral instillation of mitoxantrone in locoregional recurrence of head and neck carcinoma. Reg Cancer Treat. 1991;4:79-84.
  6. Fox ME, Smith PJ. Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells. Cancer Chemother Pharmacol. 1995;35(5):403-10.
  7. Bruix J, Sherman M. AASLD practice guidlines: Management of Hepatocellular Carcinoma. Hepatology. 2005;42(5):1208-36.
  8. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55.
  9. Shiina S, Tagawa K, Unuma T, Fugino H, Uta y, Niwa Y, Hata Y, Komatsu Y, Shiratori Y, Terano A,et al. Percutaneous ethanol injection therapy of HCC: analysis of 77 patients. AJR Am J Roentgenol. 1990;155(6):1221-6.
  10. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, Frings H, Laubenberger J, Zuber I, Blum HE, Bartolozzi C. Small hepatocellular carcinoma in cirrhosis:randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228(1):235-40.
  11. Peng ZW, Zhang YJ, Chen MS, Lin XJ, Liang HH, Shi M. Radiofrequency ablation as first-line treatment for small solitary hepatocellular carcinoma: Long-term results. Eur J Surg Oncol. 2010;36(11):1054-60.
  12. Aramaki, M.; Kawano, K.; Ohno, T, Sasaki A, Tahara K, Kai S, Iwashita Y, Kitano S. Microwave coagulation therapy for unresectable hepatocellular carcinoma. Hepatogastroenterology. 2004;51(60):1784-87.
  13. Donckier V, Van Laethem JL, Ickx B, Van